ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för oritavancin. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

16 träffar

Bibliografisk träff 2014-10-06

Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.

Corey GR, Good S, Jiang H, Moeck G, Wikler M, Green S, Manos P, Keech R, Singh R, Heller B, Bubnova N, O'Riordan W, SOLO II Investigators.

Clin Infect Dis · comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1093/cid/ciu778

Bibliografisk träff 2014-10-01

Oritavancin: first global approval.

Markham A.

Drugs · review; journal article · DOI 10.1007/s40265-014-0295-4

Bibliografisk träff 2014-09-16

In vitro activity of oritavancin against Gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013.

Karlowsky JA, Walkty AJ, Baxter MR, Adam HJ, Zhanel GG.

Diagn Microbiol Infect Dis · research support, non-u.s. gov't; journal article · DOI 10.1016/j.diagmicrobio.2014.09.003

Bibliografisk träff 2014-08-13

Glycopeptide antibiotics: back to the future.

Butler MS, Hansford KA, Blaskovich MA, Halai R, Cooper MA.

J Antibiot (Tokyo) · research support, non-u.s. gov't; review; journal article · DOI 10.1038/ja.2014.111

Bibliografisk träff 2014-07-24

Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones.

Van Bambeke F.

Ann Med · research support, non-u.s. gov't; review; journal article · DOI 10.3109/07853890.2014.935470

Bibliografisk träff 2014-07-14

Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents.

Lin G, Pankuch G, Appelbaum PC, Kosowska-Shick K.

Antimicrob Agents Chemother · brief-report; research support, non-u.s. gov't; journal article · DOI 10.1128/aac.02932-14

Bibliografisk träff 2014-06-01

Single-dose oritavancin in the treatment of acute bacterial skin infections.

Corey GR, Kabler H, Mehra P, Gupta S, Overcash JS, Porwal A, Giordano P, Lucasti C, Perez A, Good S, Jiang H, Moeck G, O'Riordan W, SOLO I Investigators.

N Engl J Med · comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1056/nejmoa1310422

Bibliografisk träff 2014-05-23

In vitro activities of oritavancin and comparators against meticillin-resistant Staphylococcus aureus (MRSA) isolates harbouring the novel mecC gene.

Arhin FF, Sarmiento I, Moeck G.

Int J Antimicrob Agents · journal article · DOI 10.1016/j.ijantimicag.2014.03.015

Bibliografisk träff 2014-02-18

Oritavancin activity against Staphylococcus aureus causing invasive infections in U.S. and European hospitals: a 5-year international surveillance program.

Mendes RE, Sader HS, Flamm RK, Farrell DJ, Jones RN.

Antimicrob Agents Chemother · brief-report; research support, non-u.s. gov't; journal article · DOI 10.1128/aac.02482-13

Bibliografisk träff 2014-02-05

Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide.

Mendes RE, Sader HS, Flamm RK, Jones RN.

J Antimicrob Chemother · research support, non-u.s. gov't; journal article · DOI 10.1093/jac/dku016

Bibliografisk träff 2014-01-21

Study of macrophage functions in murine J774 cells and human activated THP-1 cells exposed to oritavancin, a lipoglycopeptide with high cellular accumulation.

Lemaire S, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F.

Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.02475-13

Bibliografisk träff 2013-09-01

Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens.

Das B, Sarkar C, Schachter J.

Pak J Pharm Sci · review; journal article

Bibliografisk träff 2013-06-11

Evaluation of the effect of oritavancin on Clostridium difficile spore germination, outgrowth and recovery.

Chilton CH, Freeman J, Baines SD, Crowther GS, Nicholson S, Wilcox MH.

J Antimicrob Chemother · research support, non-u.s. gov't; journal article · DOI 10.1093/jac/dkt160

Bibliografisk träff 2013-01-01

Oritavancin: an investigational lipoglycopeptide antibiotic.

Karaoui LR, El-Lababidi R, Chahine EB.

Am J Health Syst Pharm · review; journal article · DOI 10.2146/ajhp110572

Bibliografisk träff 2012-10-22

Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.

Belley A, Arhin FF, Sarmiento I, Deng H, Rose W, Moeck G.

Antimicrob Agents Chemother · research-article; journal article · DOI 10.1128/aac.01428-12

Bibliografisk träff 2012-08-30

Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011.

Morrissey I, Seifert H, Canton R, Nordmann P, Stefani S, Macgowan A, Janes R, Knight D, Oritavancin Study Group.

J Antimicrob Chemother · research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1093/jac/dks344